Regeneron Pharmaceuticals Investor Presentation — February 2021

Document content

CORPORATE PRESENTATION

This presentation includes forward -looking statements thatinvolve risks anduncertainties relating tofuture events andthefuture performance ofRegeneron Pharmaceuticals, Inc.(“Regeneron” orthe“Company”), andactual events orresults may differ

materially from these forward -looking statements .Words such as“anticipate,” “expect,”“intend,”“plan,”“believe,”“seek,”“estimate,” variations ofsuch words, andsimilar expressions areintended toidentify such forward -looking statements, although notall

forward -looking statements contain these identifying words .These statements concern, andthese risks anduncertainties include, among others, theimpact ofSARS -CoV-2(thevirus thathascaused theCOVID -19pandemic) onRegeneron's business and

itsemployees, collaborators, andsuppliers andother third parties onwhich Regeneron relies, Regeneron's anditscollaborators’ ability tocontinue toconduct research andclinical programs, Regeneron's ability tomanage itssupply chain, netproduct sales

ofproducts marketed orotherwise commercialized byRegeneron and/or itscollaborators (collectively, ”Regeneron’s Products“), andtheglobal economy ;thenature, timing, andpossible success andtherapeutic applications ofRegeneron’s Products and

product candidates being developed byRegeneron and/or itscollaborators (collectively, “Regeneron’s ProductCandidates”) and research and clinical programs now underway orplanned, including without limitation EYLEA® (aflibercept) Injection,

Dupixent® (dupilumab), Libtayo® (cemiplimab), Praluent® (alirocumab), Kevzara® (sarilumab), InmazebTM (atoltivimab, maftivimab, andodesivimab -ebgn), REGEN -COV™ (casirivimab andimdevimab), fasinumab, EvkeezaTM (evinacumab), garetosmab,

Regeneron’s anditscollaborators’ other oncology programs (including odronextamab (REGN 1979 )andREGN 5458 ),Regeneron’s anditscollaborators’ other hematology programs (including pozelimab (REGN 3918 )),Regeneron’s anditscollaborators’

earlier -stage programs, andtheuseofhuman genetics inRegeneron’s research programs ;safety issues resulting from theadministration ofRegeneron’s Products andRegeneron’s Product Candidates inpatients, including serious complications orside

effects inconnection with theuseofRegeneron’s Products andRegeneron’s Product Candidates inclinical trials ;thelikelihood, timing, andscope ofpossible regulatory approval andcommercial launch ofRegeneron’s Product Candidates andnew

indications forRegeneron’s Products, including without limitation EYLEA, Dupixent, Libtayo, Praluent, Kevzara, REGEN -COV, fasinumab, Evkeeza, garetosmab, odronextamab, REGN 5458 ,andpozelimab ;thelikelihood andtiming ofachieving anyofthe

anticipated milestones described inthispresentation ;theextent towhich theresults from theresearch anddevelopment programs conducted byRegeneron and/or itscollaborators may bereplicated inother studies and/or lead toadvancement ofproduct